Effect of long-term treatment with sodium cromoglycate on nonspecific bronchial hyperresponsiveness in asthma

Abstract

Several studies in the past have demonstrated a reduction in nonspecific bronchial hyperresponsiveness subjects with seasonal extrinsic asthma after long-term treatment with sodium cromoglycate. Since sodium cromoglycate is an effective drug in the prophylactic treatment of all types of asthma, we assessed the effect of a three-month treatment on nonspecific bronchial hyperresponsiveness in 11 patients with perennial asthma. Bronchial responsiveness was determined by histamine bronchoprovocation test, using SGaw as the index of lung function and expressed as PD35SGaw. During the run-in period of one month when sodium cromoglycate was not used, the histamine PD35SGaw decreased significantly from 0.15 +/- 0.30 to 0.09 +/- 0.29 mg/ml (p less than 0.001). After three months of treatment with the drug, bronchial hyperresponsiveness was reduced significantly; the PD35SGaw was 0.21 +/- 0.29 mg/ml (p less than 0.001). It was concluded that long-term treatment of patients with perennial asthma with sodium cromoglycate results in reduced bronchial hyperresponsiveness.